ATE435297T1 - Retrovirales verabreichungssystem - Google Patents

Retrovirales verabreichungssystem

Info

Publication number
ATE435297T1
ATE435297T1 AT99922378T AT99922378T ATE435297T1 AT E435297 T1 ATE435297 T1 AT E435297T1 AT 99922378 T AT99922378 T AT 99922378T AT 99922378 T AT99922378 T AT 99922378T AT E435297 T1 ATE435297 T1 AT E435297T1
Authority
AT
Austria
Prior art keywords
retroviral
delivery system
target site
nucleotide sequence
retroviral delivery
Prior art date
Application number
AT99922378T
Other languages
English (en)
Inventor
Kyriacos Mitraphanous
Deva Patil
Alan Kingsman
Susan Mary Kingsman
Fiona Margaret Ellard
Original Assignee
Oxford Biomedica Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9811153A external-priority patent/GB2337520B/en
Application filed by Oxford Biomedica Ltd filed Critical Oxford Biomedica Ltd
Application granted granted Critical
Publication of ATE435297T1 publication Critical patent/ATE435297T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13061—Methods of inactivation or attenuation
    • C12N2740/13062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6045—RNA rev transcr viruses
    • C12N2810/6054—Retroviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Passenger Equipment (AREA)
  • Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
AT99922378T 1998-05-22 1999-05-21 Retrovirales verabreichungssystem ATE435297T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9811153A GB2337520B (en) 1998-05-22 1998-05-22 Delivery system
US9314998P 1998-07-17 1998-07-17
PCT/GB1999/001607 WO1999061639A2 (en) 1998-05-22 1999-05-21 Retroviral delivery system

Publications (1)

Publication Number Publication Date
ATE435297T1 true ATE435297T1 (de) 2009-07-15

Family

ID=26313732

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99922378T ATE435297T1 (de) 1998-05-22 1999-05-21 Retrovirales verabreichungssystem

Country Status (10)

Country Link
EP (1) EP1080216B1 (de)
JP (1) JP4612950B2 (de)
KR (1) KR20010074493A (de)
CN (1) CN1325653C (de)
AT (1) ATE435297T1 (de)
AU (1) AU763007B2 (de)
CA (1) CA2328491A1 (de)
DE (1) DE69941049D1 (de)
GB (1) GB2351290A (de)
WO (1) WO1999061639A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1238092B1 (de) * 1999-12-14 2007-01-24 Novartis AG Auf dem rinderimmunschwächevirus (biv) basierte vektoren
GB0024550D0 (de) 2000-10-06 2000-11-22 Oxford Biomedica Ltd
EP1333863A2 (de) * 2000-11-03 2003-08-13 Oxford Biomedica (UK) Limited Vektorsystem zur modifizierung von tyrosine hydroxylase-positiven neuronen
US20020168760A1 (en) * 2001-03-13 2002-11-14 Dornburg Ralph C. Retroviral vectors for gene transfer into neuronal cells
CA2344208A1 (en) 2001-04-30 2002-10-30 Oxford Biomedica (Uk) Limited Method
FR2825372B1 (fr) * 2001-06-01 2004-06-18 Centre Nat Rech Scient Pseudotypage des vecteurs vih-1 par des enveloppes de rhabdovirus
DE60230641D1 (de) * 2001-09-14 2009-02-12 Oxford Biomedica Ltd Lentivirale vektoren zur behandlung von schmerzen
ES2634424T3 (es) 2002-02-01 2017-09-27 Oxford Biomedica (Uk) Limited Vector multicistrónico lentivírico
EP1551974A1 (de) * 2002-10-04 2005-07-13 Oxford Biomedica (UK) Limited Vektorsystem
CN101014710A (zh) * 2004-09-07 2007-08-08 株式会社Macrogen 基于caev的载体系统
EP2045268B1 (de) 2005-05-13 2011-09-21 Oxford BioMedica (UK) Limited Vom Tumorantigen 5t4 abgeleitete Mhc-Klasse-I- und II-Peptidantigene
GB0526210D0 (en) 2005-12-22 2006-02-01 Oxford Biomedica Ltd Vectors
DK3192874T3 (da) 2008-06-18 2019-12-16 Oxford Biomedica Ltd Virusoprensning
HRP20140327T4 (hr) * 2009-07-24 2017-11-03 Immune Design Corp Lentiviralni vektori pseudotipizirani sa glikoproteinom ovojnice virusa sindbis
EP2575894B1 (de) 2010-05-28 2015-02-25 Oxford Biomedica (UK) Ltd Verabreichung lentiviraler vektoren ins gehirn
US20120310140A1 (en) 2010-12-01 2012-12-06 Spinal Modulation, Inc. Directed delivery of agents to neural anatomy
GB201118636D0 (en) 2011-10-28 2011-12-07 Oxford Biomedica Ltd Nucleotide sequence
US20160122727A1 (en) 2013-06-13 2016-05-05 Shire Human Genetic Therapies, Inc. Messenger rna based viral production
GB201318804D0 (en) 2013-10-24 2013-12-11 Adaptimmune Ltd Vectors for transgene expression
GB201715052D0 (en) * 2017-09-19 2017-11-01 Oxford Genetics Ltd Vectors
KR20220034719A (ko) 2019-03-10 2022-03-18 시오 진 테라피스 인코포레이티드 파킨슨병을 치료하기 위한 유전자 요법 조성물 및 방법
DE102020106710A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
WO2025240518A1 (en) 2024-05-14 2025-11-20 Dispatch Biotherapeutics, Inc. Modified lentiviral transfer plasmids

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0261940A3 (de) * 1986-09-23 1989-07-05 Applied Biotechnology, Inc. Pseudorabies-Impfstoffe und DNS-Vektoren zur Rekombination mit Poxviren
WO1992003537A1 (en) * 1990-08-15 1992-03-05 Therion Biologics Corporation Self-assembling replication defective hybrid virus particles
ATE188740T1 (de) * 1991-02-19 2000-01-15 Univ California Viruspartikel mit veraendertem wirtspektrum
EP0595970A4 (de) * 1991-07-17 1995-05-31 Commw Scient Ind Res Org Verbesserter impfstoff.
WO1993014188A1 (en) * 1992-01-17 1993-07-22 The Regents Of The University Of Michigan Targeted virus
ZA937164B (en) * 1992-09-28 1994-05-23 Commw Scient Ind Res Org Delivery system
FR2716459B1 (fr) * 1994-02-22 1996-05-10 Univ Paris Curie Système hôte-vecteur utilisable en thérapie génique.
AU3635695A (en) * 1994-09-19 1996-04-09 Board Of Trustees Of The Leland Stanford Junior University Methods for genetically modifying hematopoietic stem cells
US5739018A (en) * 1996-08-07 1998-04-14 The Regents Of The University Of California Packaging cell lines for pseudotyped retroviral vectors

Also Published As

Publication number Publication date
DE69941049D1 (de) 2009-08-13
GB0024915D0 (en) 2000-11-22
WO1999061639A2 (en) 1999-12-02
CN1302334A (zh) 2001-07-04
GB2351290A (en) 2000-12-27
EP1080216A2 (de) 2001-03-07
JP2002518997A (ja) 2002-07-02
WO1999061639A3 (en) 2000-01-27
AU763007B2 (en) 2003-07-10
CN1325653C (zh) 2007-07-11
AU3947399A (en) 1999-12-13
KR20010074493A (ko) 2001-08-04
JP4612950B2 (ja) 2011-01-12
CA2328491A1 (en) 1999-12-02
EP1080216B1 (de) 2009-07-01

Similar Documents

Publication Publication Date Title
DE69941049D1 (de) Retrovirales verabreichungssystem
UA32548C2 (uk) Ізольована послідовність днк, що кодує epsps фермент, ізольована послідовність днк, що кодує білок, який виявляє epsps активність, рекомбінантна двониткова молекула днк, спосіб одержання генетично трансформованих рослин
NO20014364D0 (no) Ny cytokin-zalphall-ligand
DK0776331T3 (da) Struktur af højere orden og binding af peptidnukleinsyrer
NO20043419L (no) Nytt cytokin, zcytor17-ligand
CY1113185T1 (el) Μεθοδοι συνενωσης αποδεκτη πεπτιδιου
NO2013009I1 (no) Alipogen tiparvovec
HUP0100094A1 (hu) Új felületi antigén
FI965031A0 (fi) Sieni, jossa AreA-geeni on muunnettu, ja Aspergillus oryzaesta peräisin oleva areA-geeni
WO1996012809A3 (fr) Sequences nucleotidiques d'antigenes retroviraux vih-1 groupe (ou sous-groupe) o
EA200200565A1 (ru) Применение клеток, трансфицированных днк, кодирующей лиганд мнс класса ii, и способ получения таких клеток
ES2143475T3 (es) Genes de polifenol oxidasa.
NO974035D0 (no) En ny vestfaktor og en genetisk sekvens som koder for denne
GB0202569D0 (en) Delivery means
BG101038A (bg) Супресия на растежа на туморни клетки посредствомсиндекан- 1 ектоучастък
DE69629808D1 (de) Promtors für gen expression
WO2002022663A3 (en) Stress resistant retroviruses
ATE264394T1 (de) Klonierung der udp-galaktose-epimerase
AU2002341238A1 (en) Diabetic model
EA199801007A1 (ru) Способ биосинтеза, позволяющий получать кобаламины
WO2001096535A3 (de) Nukleinsäure codierend eine bindungsstelle einer protein kinase der mitogenen signalisierungskaskade für ein die glykolyse katalysierendes enzym
EA200100440A1 (ru) Ген prv-1 и его применение
DK1123396T3 (da) Minimale promotorer og anvendelser deraf
ES2260624T3 (es) Deteccion de mutaciones.
EA200000705A1 (ru) Промежуточные соединения и способ синтеза 17-замещенных 16.бета.-арилокси 4-азастероидов

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties